Decision making process in oncology practice: Is the information available and what should it consist of?
Open Access
- 30 June 2005
- journal article
- research article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 54 (3) , 165-170
- https://doi.org/10.1016/j.critrevonc.2005.01.003
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- New designs for phase 2 clinical trialsBlood, 2003
- The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trialsClinical Oral Investigations, 2003
- Evaluation of response: new and standard criteriaAnnals of Oncology, 2002
- The Need for and Characteristics of Randomized, Phase III Trials to Evaluate Symptom Management in Patients With CancerJNCI Journal of the National Cancer Institute, 2002
- Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomasEuropean Journal Of Cancer, 2002
- Non-randomised phase II trials of drug combinationsEuropean Journal Of Cancer, 2002
- ‘Background to clinical guidelines in cancer’: SOR, a programmatic approach to guideline development and aftercareBritish Journal of Cancer, 2001
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based ChemotherapyJournal of Clinical Oncology, 2000
- Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancerThe Lancet, 1998
- Improving the quality of reporting of randomized controlled trials. The CONSORT statementJAMA, 1996